Priority areas

Priority areas

Obesity, Metabolism & T2D related diseases areas

  • Enhance Insulin Signaling Pathway: Mechanisms to improve insulin-dependent signal transduction ie “insulin sensitization”, without weight gain and without any PPAR mediated effects
  • Modify Energy Balance: Novel pathways to reduce caloric intake and/or increase energy expenditure (including energy diversion)
  • NASH: Metabolic, anti-inflammatory and anti-fibrotic mechanisms
  • Diabetic Kidney disease: Metabolic, anti-inflammatory and anti-fibrotic mechanisms

Immunology areas

  • IBD: Mechanisms of host-microbe interactions or cellular stress responses. Novel microbiome-based therapeutics. IBD genetics and host-environment cross talk
  • Psoriasis: Mechanisms involved in switch from guttate psoriasis to chronic plaque psoriasis
  • Rheumatology: Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Lupus

Infectious Diseases & Vaccines areas

  • Vaccines: Viral vaccines, bacterial vaccines, vaccine platforms
  • Hepatitis:  Immune activation in Hepatitis B. Novel HBV antivirals
  • Respiratory infections: RSV, influenza, rhinovirus, hMPV, PIV
  • HIV: HIV cure approaches (gene editing/recombinase/etc)

Neuroscience areas

  • Alzheimer´s: Novel approaches to treat AD other than those that directly impact on amyloid formation, deposition and disposition. Role of neuroinflammation. Investigation of the genetic risk factors for late-stage AD. Novel strategies to cross the BBB
  • Mood disorders: Novel, transformative treatments in mood disorders

Oncology areas

  • Colorectal: Targets on premalignant APC mut epithelial cells / Pathways for prevention / Vaccines with novel antigens. Microbiome targeting opportunities. Wnt/b-catenin pathway agents. Non invasive diagnostics to identify high risk patients
  • Hematological malignancies: Biology/ targets / opportunities targeting immunotherapy for AML/MDS. Epigenetic targets or metabolic pathway targets/biology/interventions. Multiple myeloma lineage specific targets / biomarkers for early disease interception. Promising new biology in hematological malignancies
  • Lung: Immune therapeutics: Novel checkpoints or new immunomodulatory mechanisms of action. Novel lung cell antigens for vaccines or immune redirection. Wnt/b-catenin pathway. Disease interception/prevention targets/biology
  • Prostate: Androgen receptor axis and resistance mechanisms. Immune therapeutics in prostate cancer: combinations with vaccines, Treg targets, Myeloid targets, oncolytic viruses. Targets/biology in early disease/prevention in prostate cancer. Targets/therapeutics for Neuroendocrine Prostate Cancer

Transversal topics areas

  • Auto-antigens / Neo-antigens and T cell receptors: Platforms/modalities to identify auto antigen(s)/TCR. Approaches to block auto antigen(s)/TCR in diseases of interest
  • Autophagy: Identification of small molecule modulators of autophagy for cancer, aging, neurodegeneration and infectious disease
  • Epigenetic modulation: Target identification. Assay formats. Small molecule modulators
  • Extreme phenotypes: Patient cohorts. Genomics. Clinical data
  • Inflammasome: Small molecule modulators. Assay formats
  • Local delivery for targeted therapeutics: Large and small molecules for prioritized disease conditions
  • Novel small molecule approaches: With biologics-like efficacy
  • Mechanisms of immune tolerance: Inhibition of signal 1 and/or signal 2 T cell stimulation. Enhancing Treg activity/abundance
  • Microbiome: Identification of new therapeutic approaches based on the human microbiome. Identification of causal relationships between microbiome composition and effect on disease
  • Orphan GPCRs: Functional characterization of orphan or poorly characterized GPCRs and link to human disease. Development of technologies to be able to study orphan GPCRs
  • Spliceosome: RNA splicing alterations. Targeting. Synthetic inhibitors
  • Vaccine platforms: adjuvants  that boost both cellular (CD4 and CD8 T cell) and humoral responses better than Alum; enhanced durability of action. RNA vaccine delivery technologies

Other transformational approaches

This is explained in greater detail in the following presentation.

In addition, projects arising from clinical observations are also of great interest to Janssen. Some examples of such projects are included in the following document.

The I2D2 initiative is sponsored by:

With the support of: